Related references
Note: Only part of the references are listed.Remote loading paclitaxel-doxorubicin prodrug into liposomes for cancer combination therapy
Jiang Yu et al.
ACTA PHARMACEUTICA SINICA B (2020)
Immunomodulators targeting the PD-1/PD-L1 protein-protein interaction: From antibodies to small molecules
Jeffrey Yang et al.
MEDICINAL RESEARCH REVIEWS (2019)
Reactive oxygen species modulate macrophage immunosuppressive phenotype through the up-regulation of PD-L1
Cecilia Roux et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Reprogramming Tumor Immune Microenvironment (TIME) and Metabolism via Biomimetic Targeting Codelivery of Shikonin/JQ1
Hairui Wang et al.
NANO LETTERS (2019)
Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial
Leonie Voorwerk et al.
NATURE MEDICINE (2019)
Current Landscape of Immunotherapy in Breast Cancer: A Review
Sylvia Adams et al.
JAMA ONCOLOGY (2019)
Antitumor Activity of 1,18-Octadecanedioic Acid-Paclitaxel Complexed with Human Serum Albumin
Cassandra E. Callmann et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2019)
Probing the impact of sulfur/selenium/carbon linkages on prodrug nanoassemblies for cancer therapy
Bingjun Sun et al.
NATURE COMMUNICATIONS (2019)
Targeting photodynamic and photothermal therapy to the endoplasmic reticulum enhances immunogenic cancer cell death
Wei Li et al.
NATURE COMMUNICATIONS (2019)
Quaternary Piperazine-Substituted Rhodamines with Enhanced Brightness for Super-Resolution Imaging
Zhiwei Ye et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2019)
Redox-Activated Porphyrin-Based Liposome Remote-Loaded with Indoleamine 2,3-Dioxygenase (IDO) Inhibitor for Synergistic Photoimmunotherapy through Induction of Immunogenic Cell Death and Blockage of IDO Pathway
Dechun Liu et al.
NANO LETTERS (2019)
Sequentially responsive biomimetic nanoparticles with optimal size in combination with checkpoint blockade for cascade synergetic treatment of breast cancer and lung metastasis
Wenqi Yu et al.
BIOMATERIALS (2019)
Immune Checkpoint Blockade Mediated by a Small-Molecule Nanoinhibitor Targeting the PD-1/PD-L1 Pathway Synergizes with Photodynamic Therapy to Elicit Antitumor Immunity and Antimetastatic Effects on Breast Cancer
Rui Zhang et al.
SMALL (2019)
Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors
K. M. Heinhuis et al.
ANNALS OF ONCOLOGY (2019)
FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia
Aviva C. Krauss et al.
CLINICAL CANCER RESEARCH (2019)
Tyrosine modified irinotecan-loaded liposomes capable of simultaneously targeting LAT1 and ATB0,+ for efficient tumor therapy
Zhenjie Wang et al.
JOURNAL OF CONTROLLED RELEASE (2019)
Nanocarrier-Mediated Chemo-Immunotherapy Arrested Cancer Progression and Induced Tumor Dormancy in Desmoplastic Melanoma
Qi Liu et al.
ACS NANO (2018)
Therapeutic efficacy of lipid emulsions of docetaxel-linoleic acid conjugate in breast cancer
Tao Zhang et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2018)
The effect of linkers on the self-assembling and anti-tumor efficacy of disulfide-linked doxorubicin drug-drug conjugate nanoparticles
Yaoqi Wang et al.
JOURNAL OF CONTROLLED RELEASE (2018)
Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas A Phase 2 Clinical Trial
Maud Toulmonde et al.
JAMA ONCOLOGY (2018)
Immunogenic cell death in anticancer chemotherapy and its impact on clinical studies
Qiang Wang et al.
CANCER LETTERS (2018)
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
L. Horn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
被撤回的出版物: Breast Cancer Chemo-immunotherapy through Liposomal Delivery of an Immunogenic Cell Death Stimulus Plus Interference in the IDO-1 Pathway (Retracted article. See vol. 15, pg. 10735, 2021)
Jianqin Lu et al.
ACS NANO (2018)
Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia (vol 78, pg 1903, 2018)
Hannah A. Blair
DRUGS (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Predictive Biomarkers for Checkpoint Immunotherapy: Current Status and Challenges for Clinical Application
Nancy Tray et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Paclitaxel: What has been done and the challenges remain ahead
Ezequiel Bernabeu et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2017)
Reduction-sensitive Paclitaxel Prodrug Self-assembled Nanoparticles with Tetrandrine Effectively Promote Synergistic Therapy Against Drug-sensitive and Multidrug-resistant Breast Cancer
Mengjuan Jiang et al.
MOLECULAR PHARMACEUTICS (2017)
Tumor Microenvironment Responsive Nanogel for the Combinatorial Antitumor Effect of Chemotherapy and Immunotherapy
Qingle Song et al.
NANO LETTERS (2017)
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
J. Bellmunt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells
Lukasz Skalniak et al.
ONCOTARGET (2017)
The battle of nano paclitaxel
Alexandros Marios Sofias et al.
ADVANCED DRUG DELIVERY REVIEWS (2017)
Immunogenic cell death in cancer and infectious disease
Lorenzo Galluzzi et al.
NATURE REVIEWS IMMUNOLOGY (2017)
Synthesis of a Gemcitabine Prodrug for Remote Loading into Liposomes and Improved Therapeutic Effect
Jonathan P. May et al.
BIOCONJUGATE CHEMISTRY (2016)
Chemotherapy and immunotherapy: mapping the road ahead
Alistair M. Cook et al.
CURRENT OPINION IN IMMUNOLOGY (2016)
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
Nicholas McGranahan et al.
SCIENCE (2016)
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
J. Naidoo et al.
ANNALS OF ONCOLOGY (2015)
Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-κB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer
Jin Peng et al.
CANCER RESEARCH (2015)
Liposomal drug delivery systems: From concept to clinical applications
Theresa M. Allen et al.
ADVANCED DRUG DELIVERY REVIEWS (2013)
Dissecting Paclitaxel-Microtubule Association: Quantitative Assessment of the 2′-OH Group
Shubhada Sharma et al.
BIOCHEMISTRY (2013)
nab-Paclitaxel mechanisms of action and delivery
Denise A. Yardley
JOURNAL OF CONTROLLED RELEASE (2013)
Low-dose paclitaxel enhances the anti-tumor efficacy of GM-CSF surface-modified whole-tumor-cell vaccine in mouse model of prostate cancer
Qiushan He et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
Development of a weak-base docetaxel derivative that can be loaded into lipid nanoparticles
Igor V. Zhigaltsev et al.
JOURNAL OF CONTROLLED RELEASE (2010)
Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse
Alain P. Vicari et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Immunogenic and tolerogenic cell death
Douglas R. Green et al.
NATURE REVIEWS IMMUNOLOGY (2009)
Low-dose paclitaxel prior to intratumoral dendritic cell vaccine modulates intratumoral cytokine network and lung cancer growth
Zhong Hua et al.
CLINICAL CANCER RESEARCH (2007)
Share Paper
